| abstract |
Referring to a compound of formula I, wherein: ring A is fused heterocycloalkyl containing oxygen (from 4 to 8 members), a fused phenyl ring, among others; R1 is selected from the group consisting of (C3-C8) cycloalkyl, (C6-C10) aryl, and heteroaryl (5 to 14 membered, among others); R2 is hydrogen, (C1-C6) alkyl, (C2-C6) alkenyl, among others; R3a is H, halogen, cyano, among others; R3b when present is H, halogen, oxo, cyano, among others; R4a when present is H, halogen, oxo, cyano, among others; R4b is H, halogen, oxo, cyano, among others; n is 0 or 1. These compounds are inhibitors of the enzyme phosphodiesterase 4 (PDE4). It also refers to methods of preparing these compounds for the treatment of diseases of the central nervous system (CNS) such as schizophrenia, depression, anxiety, among others; autoimmune or inflammatory diseases. |